News, analysis and field notes from the InteliMind team — the strategy, market and management thinking behind the work we do for our clients.
Big Pharma is experiencing a gold rush into complex biologics and peptides, while AI/ML integration compresses drug discovery timelines. However, this marriage of wet-lab biology and dry-lab computation creates a perilous frontier where algorithms design living medicines, legal stakes skyrocket, and the boundary between innovation and illusion blurs.
Fresh perspectives, published as our experts publish them — no fluff, just the thinking behind the work.
When Big Pharma Meets AI
Read the full article
Sara Pirooz